The practical question about Ashwagandha (Withania somnifera) is not simply whether it “works,” but which preparation was studied, at what dose, for which outcome, and for how long. Human trials have used dried root powder, root extracts, and root-and-leaf extracts with very different concentrations. Evidence is most consistent for possible short-term benefits in stress and sleep, but studies are generally small and do not establish one universal dose.

The Dose-Response Evidence Is Product-Specific

More milligrams do not automatically mean a stronger or safer result. The NIH Office of Dietary Supplements reports that stress and anxiety trials have used about 240–1,250 mg daily of extract or granules equivalent to 6 g of root powder. Some studies found larger effects near 500–600 mg daily, but plant part, extraction method, marker compounds, and schedule differ. Dose comparisons must therefore begin with the exact preparation.

125 mg: A Low Dose for Certain Concentrated Extracts

A 2008 randomized, double-blind, placebo-controlled trial studied a standardized root-and-leaf extract in chronically stressed adults at 125 mg once daily, 125 mg twice daily, or 250 mg twice daily for 60 days. The 125 mg once-daily group improved more than placebo on the modified Hamilton Anxiety Scale and several measures including cortisol and C-reactive protein. Of 130 enrolled participants, 98 completed the study.

This does not mean that 125 mg of ordinary root powder, or of any unrelated extract, is effective. It shows that a low dose can be active when the preparation is concentrated and characterized.

300 mg Twice Daily: A Common Research Schedule

A 2012 trial randomized 64 adults with chronic stress to a high-concentration root extract or placebo. The treatment schedule was 300 mg twice daily for 60 days. Compared with placebo, the extract group had larger improvements on validated stress scales and a greater reduction in serum cortisol; reported adverse effects were mild and similar between groups.

A 2017 pilot trial enrolled 50 adults with mild cognitive impairment and used 300 mg of root extract twice daily for eight weeks. The treatment group improved on measures of memory, executive function, sustained attention, and information-processing speed. This small study does not prove that the same dose enhances cognition in every healthy adult.

600 mg Daily: Strength and Thyroid Findings

In the 2015 Wankhede trial, 57 young men with little resistance-training experience were randomized to 300 mg of root extract twice daily or placebo during an eight-week training program. The Ashwagandha group had greater gains in measured strength and muscle size, with differences in testosterone and a muscle-recovery marker. The narrow population and short duration limit generalization.

A small thyroid trial enrolled 50 adults with subclinical hypothyroidism and used 300 mg of root extract twice daily for eight weeks. TSH, T3, and T4 changed significantly compared with placebo. This is a safety-relevant endocrine effect, not permission to self-treat thyroid disease. Case reports also describe thyrotoxicosis or thyroiditis after Ashwagandha use.

KSM-66 and Sensoril Are Not Interchangeable

KSM-66 and Sensoril are proprietary preparations made from different plant material: NIH summaries identify KSM-66 studies as using root extract and Sensoril studies as using root-and-leaf extract. Their milligram amounts cannot be compared directly without considering extraction ratio, standardization, analytical method, and the exact formulation used in the trial.

Preparation Material Research example Interpretation
KSM-66 or similar extract Root Often 300 mg twice daily in cited trials Apply only to a comparable root extract
Sensoril or similar extract Root and leaf 125 mg once daily to 250 mg twice daily Lower milligrams may still be concentrated
Traditional churna Dried mature root API dose: 3–6 g Not equivalent to an extract

The cited trials do not establish that one brand is inherently “energizing,” another “calming,” or that split dosing produces superior blood levels. Timing should follow the studied protocol, product directions, and individualized clinical advice.

What About Traditional Ashwagandha Churna?

The Ayurvedic Pharmacopoeia of India defines Ashwagandha as the dried mature root of Withania somnifera. Its profile is tikta and kashaya rasa, laghu guna, ushna virya, and madhura vipaka. Listed actions include rasayana, balya, vajikarana, and reducing aggravated Vata and Kapha. The adult powder dose is 3–6 g.

That dose applies to authenticated root powder, not a standardized extract. The API monograph gives a powder dose but does not direct every user to take it with milk, ghee, and sugar. Human evidence was not found proving that milk universally increases withanolide bioavailability, and a fixed dose of Pippali should not be added automatically as a “bioenhancer.”

A Safer Dose-Selection Protocol

Instead of escalating through preset doses, use a product-specific and clinically supervised process. The aim is to determine whether a clearly identified preparation provides meaningful benefit without new symptoms, interactions, or laboratory changes.

Phase 1: Identify the Exact Preparation

Record the botanical name, plant part, amount per capsule, daily serving, extract ratio, marker specification, other ingredients, batch number, and manufacturer. “500 mg Ashwagandha” is incomplete information because it may describe powder, root extract, root-and-leaf extract, or a blend.

  • Choose a product with botanical identity and contaminant testing.
  • Do not combine two Ashwagandha products during assessment.
  • Check whether the amount is per capsule or per daily serving.

Phase 2: Define the Goal and Baseline

Define one main outcome, such as perceived stress or sleep quality, and record it for at least one week. Also track alertness, digestive symptoms, resting pulse, and medicine changes. Exercise users should keep training variables stable.

Phase 3: Start Only After Safety Screening

A starting dose should come from the exact label, a trial using a comparable preparation, or a qualified practitioner. Research examples range from 125 mg daily for a concentrated root-and-leaf extract to 300 mg twice daily for certain root extracts, while the API powder dose is 3–6 g. These are reference ranges, not personal prescriptions.

Phase 4: Reassess Before Increasing

Most stress studies lasted about six to eight weeks, while safety evidence is mainly short term and insufficient for firm conclusions about long-term use. Review benefit, adverse effects, medicines, and continuing need before changing the dose. Lack of benefit does not prove that a higher dose will work.

Phase 5: Stop for Warning Signs

Stop the product and seek medical advice for jaundice, dark urine, pale stools, severe itching, persistent vomiting, marked abdominal pain, unusual fatigue, palpitations, tremor, heat intolerance, unexplained weight loss, or pronounced drowsiness. These can signal liver injury, thyroid excess, an interaction, or another condition needing assessment.

Adverse Effects and Interactions

Ashwagandha is often tolerated in short trials, but it is not risk-free. NCCIH lists drowsiness, stomach upset, diarrhea, and vomiting among possible adverse effects. Rare liver injury has been linked to Ashwagandha supplements, and thyroid changes have been documented in trials and case reports.

  • Digestive effects: nausea, abdominal discomfort, loose stools, diarrhea, or vomiting.
  • Drowsiness: avoid driving or hazardous work if alertness is reduced.
  • Thyroid effects: it may alter TSH, T3, or T4 and interact with thyroid hormone.
  • Liver warning: jaundice, dark urine, pale stools, itching, or persistent abdominal symptoms need prompt review.
  • Interactions: possible with sedatives, anticonvulsants, immunosuppressants, thyroid hormone, and medicines for diabetes or high blood pressure.

Who Should Not Self-Experiment?

Unsupervised use is inappropriate during pregnancy or breastfeeding and for people approaching surgery, living with autoimmune or thyroid disorders, or taking interacting medicines. Existing liver disease, abnormal liver tests, or a previous supplement-related liver reaction also warrants medical review.

  • Pregnant or breastfeeding people
  • People with thyroid, autoimmune, or liver disease
  • People taking thyroid hormone, immunosuppressants, sedatives, anticonvulsants, diabetes medicines, or blood-pressure medicines
  • People preparing for surgery or anesthesia
  • People with hormone-sensitive prostate cancer, because Ashwagandha may raise testosterone in some settings

Combining Ashwagandha with other Ayurvedic herbs should follow a formulation rationale and professional assessment, not the assumption that all “adaptogens” are compatible. A dosha constitution guide can support education, but it cannot replace screening for medicines, thyroid disease, liver risk, pregnancy, or surgery.

The bottom line is preparation-specific: 125 mg may be meaningful for one concentrated root-and-leaf extract, 600 mg daily has been studied for several root extracts, and 3–6 g is the API range for root powder. These amounts are not interchangeable. Use the lowest appropriate dose supported for the exact preparation and purpose, and do not escalate solely because a lower dose has not produced an immediate effect.

This article is for educational purposes and does not diagnose, treat, or prescribe. Consult a qualified Ayurvedic practitioner or healthcare provider before starting, increasing, combining, or continuing Ashwagandha, especially when taking prescription medicines or managing a chronic condition.

References

  1. NIH Office of Dietary Supplements
  2. Scispace (scispace.com)
  3. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed
  4. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions (2017), PubMed
  5. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial (2015), PubMed Central
  6. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial (2018), PubMed
  7. Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia (2022), PubMed Central
  8. Ayurvedic Pharmacopoeia of India
  9. NCCIH
Tags: Ashwagandha dose KSM-66 optimization personal research Sensoril